208 related articles for article (PubMed ID: 30299291)
1. Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
Lambertini M; Viglietti G; de Azambuja E
Curr Opin Oncol; 2019 Jan; 31(1):43-51. PubMed ID: 30299291
[TBL] [Abstract][Full Text] [Related]
2. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Chlebowski RT; Pan K; Col NF
Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
[TBL] [Abstract][Full Text] [Related]
3. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
4. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
5. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
J Clin Oncol; 2016 May; 34(14):1689-701. PubMed ID: 26884586
[TBL] [Abstract][Full Text] [Related]
9. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
[TBL] [Abstract][Full Text] [Related]
10. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
Paridaens RJ; Gelber S; Cole BF; Gelber RD; Thürlimann B; Price KN; Holmberg SB; Crivellari D; Coates AS; Goldhirsch A
Breast Cancer Res Treat; 2010 Aug; 123(1):303-10. PubMed ID: 20195744
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Francis PA
Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
[TBL] [Abstract][Full Text] [Related]
16. The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer.
Jain S; Santa-Maria CA; Gradishar WJ
Oncology (Williston Park); 2015 Jul; 29(7):473-8, 481. PubMed ID: 26178334
[TBL] [Abstract][Full Text] [Related]
17. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Perrone F; De Laurentiis M; De Placido S; Orditura M; Cinieri S; Riccardi F; Ribecco AS; Putzu C; Del Mastro L; Rossi E; Tinessa V; Mosconi AM; Nuzzo F; Di Rella F; Gravina A; Iodice G; Landi G; Pacilio C; Forestieri V; Lauria R; Fabbri A; Ibrahim T; De Maio E; Barni S; Gori S; Simeon V; Arenare L; Daniele G; Piccirillo MC; Normanno N; de Matteis A; Gallo C
Eur J Cancer; 2019 Sep; 118():178-186. PubMed ID: 31164265
[TBL] [Abstract][Full Text] [Related]
19. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
20. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
